Proactive Investors - Run By Investors For Investors

Cancer Genetics shares jump on new loan forbearance agreement

A new loan amendment with Silicon Valley Bank requires the biotech to comply with certain milestones in connection with a potential strategic transaction
blood in vials and cancerous cells
Based in Rutherford, New Jersey, Cancer Genetics offers diagnostic products and services that enable precision medicine in oncology

Shares of Cancer Genetics (NASDAQ:CGIX) are gaining ground in Thursday’s pre-market session thanks to the release of amended terms for a forbearance agreement with its lenders.

According to an 8K regulatory filing with the US Securities and Exchange Commission on Wednesday, the biotech’s new loan amendment with Silicon Valley Bank alters the interest rate to WSJ Prime plus 2.25 percentage points (which means it is 6.75% as of the close of September). It also requires the biotech to comply with certain milestones in connection with a potential strategic transaction.

READ: Cancer Genetics CEO says merger with NovellusDx to speed up enrollment in cancer-focused trials

The company also amended its loan agreement with Partners for Growth, which also outlines milestones for a possible strategic transaction. That loan agreement is an interest-only term loan of $6 million, which bears interest at the rate of 11.5% per year and matures on March 22, 2020.

In response to hints that Cancer Genetics will strike a strategic transaction, investors sent Cancer Genetics shares up 38% to $0.36 before the opening bell on Thursday.

Based in Rutherford, New Jersey, Cancer Genetics offers diagnostic products and services that enable precision medicine in oncology. It boasts clinical research collaborations with key cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

Contact Ellen Kelleher at [email protected]

View full CGIX profile View Profile

Cancer Genetics Incorporated Timeline

Related Articles

scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use